Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2

作者：

Bhutani, Manisha ^{[1
]}

Robinson, Myra ^{[2
]}

Atrash, Shebli ^{[1
]}

Paul, Barry ^{[1
]}

Pineda-Roman, Mauricio ^{[1
]}

Foureau, David ^{[3
]}

Varga, Cindy ^{[1
]}

Friend, Reed ^{[1
]}

Begic, Xhevahire ^{[4
]}

Norek, Sarah ^{[4
]}

Drennan, Tiffany ^{[5
]}

Anderson, Michelle B. ^{[6
]}

Symanowski, James ^{[2
]}

Voorhees, Peter M. ^{[7
]}

Usmani, Saad Z. ^{[8
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[2] Atrium Hlth, Levine Canc Inst, Dept Canc Biostat, Charlotte, NC USA

[3] Atrium Hlth, Levine Canc Inst, Immune Monitoring Core Lab, Charlotte, NC USA

[4] Atrium Hlth, Levine Canc Inst, Sponsored Res Coordinating Ctr, Charlotte, NC USA

[5] Atrium Hlth, Levine Canc Inst, Clin Trials Unit, Charlotte, NC USA

[6] Atrium Hlth, Levine Canc Inst, Biostat & Data Sci, Charlotte, NC USA

[7] Wake Forest Univ, Sch Med, Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Levine Canc, Charlotte, NC USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Watts, Nicole
Paul, Barry
Chhabra, Saurabh
Korde, Neha
Begic, Xhevahire
Foureau, David M.
Chung, David J.
Pineda-Roman, Mauricio
Koya, Brinda
Varga, Cindy
Ai, Jing
Daniels, Natonya
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Jewell, Ashley N.
Eldridge, Paul W.
Acampora, Donna
Symanowski, James T.
Costa, Luciano J.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 4393 - 4395
[2] Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
Bhutani, Manisha
Robinson, Myra
Paul, Barry
Atrash, Shebli
Varga, Cindy
Begic, Xhevahire
Foureau, David M.
Pineda-Roman, Mauricio
Koya, Brinda
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Acampora, Donna
Symanowski, James T.
Voorhees, Peter M.
Usmani, Saad
BLOOD, 2022, 140 : 4440 - 4441
[3] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond L.
Wang, Jianping
de Boer, Carla
Deraedt, William
Weiss, Brendan M.
Schecter, Jordan M.
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
[4] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Costa, Luciano
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai
Schmidt, Timothy
Silbermann, Rebecca
Godby, Kelly
Dhakal, Binod
Bal, Susan
Giri, Smith
D'Souza, Anita
Cornell, Robert
Hardwick, Pamela
Omel, James
Hari, Parameswaran
Callander, Natalie S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S33 - S33
[5] Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
Bhutani, Manisha
House, Monika
He, Jiaxian
Atrash, Shebli
Foureau, David M.
Paul, Barry
Friend, Reed
Symanowski, James T.
Norek, Sarah
Begic, Xhevahire
Acampora, Donna
Farmer, Katherine K.
Syfert, Carrie Ann
Pineda-Roman, Mauricio
Voorhees, Peter
Usmani, Saad Z.
BLOOD, 2020, 136
[6] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Derman, Benjamin A.
Cooperrider, Jennifer
Rosenblatt, Jacalyn
Avigan, David E.
Rampurwala, Murtuza
Barnidge, David
Major, Ajay
Karrison, Theodore
Jiang, Ken
Ramsland, Aubrianna
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[7] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Costa, Luciano J.
Chhabra, Saurabh
Godby, Kelly N.
Medvedova, Eva
Cornell, Robert F.
Hall, Aric C.
Silbermann, Rebecca W.
Innis-Shelton, Racquel
Dhakal, Binod
DeIdiaquez, Diego
Hardwick, Pamela
Biru, Yelak
Omel, James L.
Hari, Parameswaran
Callander, Natalie Scott
BLOOD, 2019, 134
[8] Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus /- daratumumab induction regimen
Meseha, Mina
Abusamra, Murad
Farooki, Azeez
Derkach, Andriy
Maclachlan, Kylee
Hultcrantz, Malin
Hassoun, Hani
Shah, Urvi
Lu, Sydney
Mailankody, Sham
Patel, Dhwani
Lahoud, Oscar
Shah, Gunjan
Scordo, Michael
Chung, David
Landau, Heather
Lesokhin, Alexander
Korde, Neha
Giralt, Sergio
Usmani, Saad
Tan, Carlyn
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S139 - S140
[9] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
Sborov, Douglas
Baljevic, Muhamed
Reeves, Brandi
Laubach, Jacob
Efebera, Yvonne
Rodriguez, Cesar
Costa, Luciano
Chari, Ajai
Silbermann, Rebecca
Holstein, Sarah
Anderson, Larry D., Jr.
Kaufman, Jonathan
Shah, Nina
Pei, Huiling
Patel, Sharmila
Cortoos, Annelore
Bartlett, Blake
Vermeulen, Jessica
Lin, Thomas
Voorhees, Peter
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S135 - S136
[10] Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
Gay, Francesca Maria
Scalabrini, Delia Rota
Belotti, Angelo
Offidani, Massimo
Petrucci, Maria Teresa
Esma, Fabrizio
Palmas, Angelo D.
Caravita, Tommaso
Grasso, Mariella
Aquino, Sara
Gamberi, Barbara
Zambello, Renato
Ledda, Antonio
Montefusco, Vittorio
Omede, Paola
Galli, Monica
Cavo, Michele
Palumbo, Antonio
Musto, Pellegrino
Boccadoro, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →